US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.85 against a street estimate of 0.72 — a beat of 18.1%.
Analysts rate Phibro Animal Health Corporation a hold (1 buy, 2 hold, 1 sell out of 4) with an average price target of $44.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.93% |
| FMR Inc | 7.78% |
| State Street Corp | 2.56% |
| Millennium Management LLC | 2.31% |
| Vanguard Capital Management, LLC | 2.27% |
| Geode Capital Management, LLC | 1.62% |
| Lord, Abbett & Co LLC | 1.61% |
| Dimensional Fund Advisors, Inc. | 1.31% |
| Document | Date |
|---|---|
| Proxy statement · Q2 FY2027 PHIBRO ANIMAL HEALTH CORPORATION — PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of three Class I Directors — | 2026-09-18 |
| Annual report FY2026 PHIBRO ANIMAL HEALTH CORPORATION – FORM 10-K SUMMARY Fiscal Year Ended June 30, 2026 --- HEADLINE NUMBERS • Total Net Sales (FY 2026): $1,518 milli | 2026-08-26 |
| Results announced · Q1 FY2027 PHIBRO ANIMAL HEALTH CORPORATION – FINANCIAL SUMMARY HEADLINE NUMBERS FISCAL YEAR 2026 (Year Ended June 30, 2026) • Net sales: $1,518.1 million, up | 2026-08-26 |
| Company announcement · Q1 FY2027 PHIBRO ANIMAL HEALTH CORPORATION (PAHC) - FORM 8-K SUMMARY HEADLINE NUMBERS • Quarterly cash dividend declared at $0.12 per share on Class A and Cla | 2026-07-28 |
| Board / officer change · Q4 FY2026 PHIBRO ANIMAL HEALTH CORPORATION – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Daniel (Dani) Bendheim appointed as Chief Executive Officer and | 2026-06-26 |
| Quarterly report · Q3 FY2026 PHIBRO ANIMAL HEALTH CORPORATION – Q3 2026 (9 MONTHS ENDED MARCH 31, 2026) HEADLINE NUMBERS • Net sales (9 months): $1,121,346 thousand, up 22.2% fr | 2026-05-06 |
| Results announced · Q4 FY2026 PHIBRO ANIMAL HEALTH CORPORATION — Q3 FY2026 SUMMARY HEADLINE NUMBERS • Net sales Q3: $383.5 million, up 10% ($35.7 million) vs. Q3 FY2025 • Net inc | 2026-05-06 |
| Quarterly report · Q2 FY2026 PHIBRO ANIMAL HEALTH CORPORATION – Q2 FY2026 SUMMARY For Period Ended December 31, 2025 --- HEADLINE NUMBERS • Net sales (6 months): $737.8 million | 2026-02-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.12 / share ex-date Sep 2, 2026 · pay Sep 23, 2026 | 2026-09-02 |
| Dividend | $0.12 / share ex-date Jun 3, 2026 · pay Jun 24, 2026 | 2026-06-03 |
| Dividend | $0.12 / share ex-date Mar 4, 2026 · pay Mar 25, 2026 | 2026-03-04 |
| Dividend | $0.12 / share ex-date Nov 26, 2025 · pay Dec 17, 2025 | 2025-11-26 |
| Announcement | Date |
|---|---|
| Q1 FY2026 results announced and financial guidance provided for fiscal year Phibro Animal Health Corporation held its annual stockholder meeting on November 4, 2025, with strong attendance (97.3% of voting power present). All four proposals passed decisively: three | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Phibro Animal Health Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.